Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  daunorubicin hydrochloride
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 67 for your search:
Start Over
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)
Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 65
Sponsor: Other
Protocol IDs: GMALL01, NCT00198991
AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia
Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: MK1-192, NCT00180128
LAL-BR/2001: Study Treatment to Low Risk ALL
Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 and under
Sponsor: Other
Protocol IDs: LAL-BR/2001, NCT00526175
Treatment of High Risk Adult Acute Lymphoblastic Leukemia
Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: LAL-AR/2003, NCT00853008
Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE
Phase: Phase IV
Type: Treatment
Status: Active
Age: 55 and under
Sponsor: Other
Protocol IDs: LAL Ph-2008, NCT01491763
Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS
Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 60
Sponsor: Other
Protocol IDs: LAL-AR/2011, NCT01540812
Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: APL2012, NCT01987297
Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia
Phase: Phase IV
Type: Treatment
Status: Active
Age: 6 months to 18 years
Sponsor: Other
Protocol IDs: CCALL2012, NCT01990807
Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia
Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 30
Sponsor: Other
Protocol IDs: LAL-RI/2008, NCT02036489
Clofarabine or High-Dose Cytarabine and Pegaspargase in Children With ALL
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 1 to 17
Sponsor: Other
Protocol IDs: CDR0000686545, 2009-012758-18, GPOH-COALL-08-09, EUDRACT-2009-012758-18, EU-21076, NCT01228331
High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)
Phase: Phase III
Type: Treatment
Status: Active
Age: 25 to 65
Sponsor: Other
Protocol IDs: JALSG ALL202-O, NCT00131027
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR005143, EPOANE3010, 2005-001817-17, NCT00338286
Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: NCI, Other
Protocol IDs: TOTXVI, 5R01CA140729, 5F32CA141762, R37CA036401, 5R01CA090246, Aspar PK-PD-T16, NCI-2011-01254, NCT00549848
Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 21 and under
Sponsor: NCI, Other
Protocol IDs: AML08, 5R01CA138744, 1R01CA115422, NCT00703820
Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: CDR0000613220, MOTOL-ALL-IC-BFM-2002, EU-20871, ALL-IC-BFM-2002, NCT00764907
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 60 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000659585, ECOG-E2906, E2906, NCT01041703
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 18
Sponsor: Other
Protocol IDs: AIEOP-BFM ALL 2009, NCT01117441
Idarubicin Versus High Dose Daunorubicin in Acute Myelogenous Leukemia (AML)
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: C-022, NCT01145846
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Under 30
Sponsor: NCI
Protocol IDs: NCI-2011-02670, COG-AAML1031, CDR0000701850, AAML1031, U10CA180886, U10CA098543, NCT01371981
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 30
Sponsor: NCI, Other
Protocol IDs: AALL1131, NCI-2011-03797, CDR0000706370, U10CA098543, COG-AALL1131, NCT01406756
Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML<60a
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: AML 2002 #061, NCT01414231
Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>60a
Phase: Phase III
Type: Treatment
Status: Active
Age: Over 60
Sponsor: Other
Protocol IDs: OSHO#069, NCT01497002
Safety and Efficacy Study of Ara-c at 18 gm/m2 Versus 12 gm/m2 for 3 Cycles Each in AML Consolidation
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: AML HIDAC, AIIMS, NCT01615757
Efficacy of Aprepitant (Emend®) in Children
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 20 and under
Sponsor: Other
Protocol IDs: 0413, NCT01661335
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 15 to 60
Sponsor: NCI
Protocol IDs: NCI-2013-00490, PS1203_A06PAMDREVW01, SWOG-S1203, S1203, U10CA180888, U10CA032102, NCT01802333
Start Over